Vesalius Therapeutics focuses on developing innovative approaches to treat common diseases, utilizing proprietary patient-derived models to screen drug candidates and identify new therapeutic targets.

Vesalius Therapeutics

Vesalius Therapeutics | 2,231 followers on LinkedIn. Pioneering a revolutionary platform to generate breakthrough treatments for common diseases | Pioneering a revolutionary platform to generate breakthrough treatments for common diseases.

Data Solutions Architect

Nick B.

Senior Vice President and Head of Drug Discovery at Vesalius Therapeutics (formerly Serqet Therapeutics)

Ben Munoz

Talita Turnier

SVP Platform Development, Vesalius Therapeutics | Research leader | Platform development and operation | Data science | Target discovery/validation |…

Chris Cotsapas

Vesalius and GSK share the conviction that targeting the causal factors of common diseases like Parkinson’s disease is the key to developing breakthrough medicines faster and with a higher probability of success. Read more: https://lnkd.in/eSZmP-Vz #ParkinsonsDisease #ParkinsonsAwareness #Biotech #Parkinsons

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all. https://lnkd.in/epadgTVp

Our CEO Christopher Austin describes how Vesalius has developed the first precision platform for common diseases and what’s ahead for the company as its lead candidates approach the clinic.

Our CEO Christopher Austin had a great discussion last week with colleagues at the Flagship Pioneering studio on the opportunities for bioplatforms to dramatically scale the creation of new medicines while also finding novel ways to treat common diseases with a level of precision that was previously reserved for rare diseases. #JPM2024

In Flagship’s 2024 Annual Letter, founder and CEO @Noubar Afeyan reflects on navigating through polycrisis and what it will take to make bigger leaps for patients and the planet including {novel partnerships, continuous innovation, global reach, both forms of AI} Read his annual newsletter here: https://lnkd.in/ez-KuWxi #FlagshipFounded

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 13, 2024 1:44 AM	e8ebbdf7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 13, 2024 1:44 AM	6a60e2cd
crunchbase trigger	general	Nov 13, 2024 1:44 AM	9c6f56c6
crunchbase profile	general
li profile	general	Nov 13, 2024 1:44 AM	9292776a
translate crunchbase fundingrounds	general
peers	general	Nov 13, 2024 1:44 AM	599d18c1
news basic	general	Nov 13, 2024 1:44 AM	f422a894
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

VESA

COM:VESALIUSTX

Vesalius Therapeutics